AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24301228 — intervention group
Group type: COMPARATOR
Intervention: Control vaccine (recombinant hepatitis B)
Number of subjects: 3308
Study 22422823 — intervention group
Group type: EXPERIMENTAL
Intervention: VDCR (Bortezomib, Dexamethasone, Cyclophosphamide, and Lenalidomide)
Number of subjects: 0
Study 22422823 — intervention group
Group type: EXPERIMENTAL
Intervention: VDR (Bortezomib, Dexamethasone, and Lenalidomide)
Number of subjects: 0
Study 22422823 — intervention group
Group type: EXPERIMENTAL
Intervention: VDC (Bortezomib, Dexamethasone, and Cyclophosphamide)
Number of subjects: 0
Study 22422823 — intervention group
Group type: EXPERIMENTAL
Intervention: VDC-mod (Bortezomib, Dexamethasone, and modified Cyclophosphamide)
Number of subjects: 0
Study 20002013 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid enteral feeding advancement at 30 mL/kg/day
Number of subjects: 100
Study 20002013 — intervention group
Group type: COMPARATOR
Intervention: Slow enteral feeding advancement at 20 mL/kg/day
Number of subjects: 100
Study 18487613 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomifene citrate plus metformin
Number of subjects: 225
Study 18487613 — intervention group
Group type: COMPARATOR
Intervention: Clomifene citrate plus placebo
Number of subjects: 225
Study 16183794 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral magnesium-containing drugs
Number of subjects: 4290
Study 16183794 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (control group without magnesium drugs)
Number of subjects: 4290
Study 16183794 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased serum Mg/Ca
Number of subjects: 4290
Study 14581795 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine-supplemented parenteral nutrition (n = 17)
Number of subjects: 35
Study 14581795 — intervention group
Group type: COMPARATOR
Intervention: Standard parenteral nutrition (n = 18)
Number of subjects: 35
Study 10791177 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal occult blood testing
Number of subjects: 0
Study 10791177 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible sigmoidoscopy
Number of subjects: 0
Study 10791177 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening methods (general)
Number of subjects: 0
Study 8997676 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic probe
Number of subjects: 20
Study 8997676 — intervention group
Group type: COMPARATOR
Intervention: Conventional probe
Number of subjects: 20
Study 1593867 — intervention group
Group type: EXPERIMENTAL
Intervention: Enriched, warm, leukocyte-depleted blood (Group II)
Number of subjects: 32
Study 1593867 — intervention group
Group type: COMPARATOR
Intervention: Enriched, warm, whole blood (Group I)
Number of subjects: 32
Study 2578880 — intervention group
Group type: EXPERIMENTAL
Intervention: CAP (cyclophosphamide, doxorubicin, and cisplatin)
Number of subjects: 45
Study 2578880 — intervention group
Group type: COMPARATOR
Intervention: m-AMSA (amsacrine)
Number of subjects: 45
Study 30471270 — intervention group
Group type: EXPERIMENTAL
Intervention: Solriamfetol
Number of subjects: 122
Study 30471270 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 122
Study 30356217 — intervention group
Group type: EXPERIMENTAL
Intervention: Community organizers who installed solar panels through the programme
Number of subjects: 1400000
Study 30356217 — intervention group
Group type: COMPARATOR
Intervention: Community organizers who did not install solar panels through the programme
Number of subjects: 1400000
Study 26740683 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy Deprivation (ED)
Number of subjects: 21
Study 25972515 — intervention group
Group type: EXPERIMENTAL
Intervention: Daikenchuto (15.0 g/day, t.i.d)
Number of subjects: 336
Study 25972515 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 336
Study 25972515 — intervention group
Group type: EXPERIMENTAL
Intervention: Daikenchuto
Number of subjects: 336
Study 22406958 — intervention group
Group type: EXPERIMENTAL
Intervention: Dedicated NIV ventilator
Number of subjects: 15
Study 22406958 — intervention group
Group type: COMPARATOR
Intervention: ICU ventilator without NIV algorithm
Number of subjects: 15
Study 22406958 — intervention group
Group type: COMPARATOR
Intervention: ICU ventilator with NIV algorithm
Number of subjects: 15
Study 19619900 — intervention group
Group type: EXPERIMENTAL
Intervention: Psycho-educational intervention
Number of subjects: 104
Study 19619900 — intervention group
Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 104
Study 18759642 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 110
Study 18759642 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 110
Study 18759642 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 110
Study 16124431 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin, single dose of 50, 100, 150, or 200 microg/kg bodyweight
Number of subjects: 20
Study 16124431 — intervention group
Group type: COMPARATOR
Intervention: Albendazole, 400 mg twice a day for 14 days
Number of subjects: 20
Study 12869342 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital-at-home
Number of subjects: 78
Study 10480630 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide (200 mg/day for 4 weeks)
Number of subjects: 31
Study 10480630 — intervention group
Group type: COMPARATOR
Intervention: Zidovudine and lamivudine (ZDV/LMV) for 14 days
Number of subjects: 31
Study 8916820 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 4 mg in 10 ml 0.9% saline
Number of subjects: 89
Study 8916820 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (Group PP)
Number of subjects: 89
Study 8916820 — intervention group
Group type: COMPARATOR
Intervention: Ondansetron (Group O)
Number of subjects: 89
Study 8916820 — intervention group
Group type: COMPARATOR
Intervention: Propofol (Group PI)
Number of subjects: 89
Study 8916820 — intervention group
Group type: COMPARATOR
Intervention: Propofol (Group PIP)
Number of subjects: 89
Study 2064488 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent intravenous (IV) injections of morphine sulfate 4 mg every 30 to 60 minutes (phase 1)
Number of subjects: 47
Study 2064488 — intervention group
Group type: COMPARATOR
Intervention: Patient-controlled analgesia (PCA) with morphine sulfate 2 mg bolus then 1.0 mg with a 6-minute lockout (phase 1)
Number of subjects: 47
Study 2064488 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent intravenous (IV) injections of morphine sulfate 8 mg every 30 to 60 minutes (phase 2)
Number of subjects: 47
Study 2064488 — intervention group
Group type: COMPARATOR
Intervention: Patient-controlled analgesia (PCA) with morphine sulfate 5 mg bolus then 2.7 mg with a 10-minute lockout (phase 2)
Number of subjects: 47
Study 6698443 — intervention group
Group type: EXPERIMENTAL
Intervention: High sugar diet (112 g refined sucrose)
Number of subjects: 12
Study 6698443 — intervention group
Group type: COMPARATOR
Intervention: Low sugar diet (16 g refined sucrose)
Number of subjects: 12
Study 31256656 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructosamine > 293 µmol/l
Number of subjects: 1119
Study 31256656 — intervention group
Group type: COMPARATOR
Intervention: HbA1c cut-offs (7% and 7.5%)
Number of subjects: 1119
Study 30270717 — intervention group
Group type: EXPERIMENTAL
Intervention: ONCE PRO (meal replacement)
Number of subjects: 110
Study 30270717 — intervention group
Group type: COMPARATOR
Intervention: Controlled diet
Number of subjects: 110
Study 30270717 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 110
Study 27056766 — intervention group
Group type: EXPERIMENTAL
Intervention: OCT-guided PCI
Number of subjects: 214
Study 27056766 — intervention group
Group type: COMPARATOR
Intervention: Angiography-guided PCI
Number of subjects: 214
Study 24559020 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold X5 hairlaser device
Number of subjects: 2
Study 24559020 — intervention group
Group type: COMPARATOR
Intervention: Sham device (control group)
Number of subjects: 2
Study 18394612 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole 1 mg (group A1)
Number of subjects: 32
Study 18394612 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole 5 mg (group A5)
Number of subjects: 32
Study 18394612 — intervention group
Group type: COMPARATOR
Intervention: Clomiphene citrate 50 mg (group CC50)
Number of subjects: 32
Study 16358550 — intervention group
Group type: EXPERIMENTAL
Intervention: MCT/LCT fat emulsions
Number of subjects: 30
Study 16358550 — intervention group
Group type: COMPARATOR
Intervention: LCT fat emulsions
Number of subjects: 30
Study 12174335 — intervention group
Group type: EXPERIMENTAL
Intervention: RC-Cornet device
Number of subjects: 14
Study 12174335 — intervention group
Group type: COMPARATOR
Intervention: Normal exaspiratory valve
Number of subjects: 14
Study 9220304 — intervention group
Group type: COMPARATOR
Intervention: Standard Cognitive Therapy (SCT)
Number of subjects: 40
Study 9220304 — intervention group
Group type: EXPERIMENTAL
Intervention: Focused Cognitive Therapy (FCT)
Number of subjects: 40
Study 8192475 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg of vancomycin per kg of body weight before anesthesia
Number of subjects: 20
Study 8192475 — intervention group
Group type: COMPARATOR
Intervention: 15 mg of vancomycin per kg of body weight before anesthesia and a second 7.5‐mg/kg dose at the time of initiation of cardiopulmonary bypass
Number of subjects: 20
Study 3791247 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg AZQ/m2/day, i.v., for 3 consecutive days, every 4 weeks
Number of subjects: 2
Study 3791247 — intervention group
Group type: COMPARATOR
Intervention: 200 mg BCNU/m2, i.v., every 8 weeks
Number of subjects: 2
Study 782704 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg digoxin i.v.
Number of subjects: 15
Study 782704 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline solution)
Number of subjects: 15
Study 31484340 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence to WCRF/AICR recommendations (highest score category)
Number of subjects: 2267
Study 31484340 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence to WCRF/AICR recommendations (lowest score category)
Number of subjects: 2267
Study 29191845 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time continuous glucose monitoring (CGM) used for an average of 5 days/week.
Number of subjects: 0
Study 29191845 — intervention group
Group type: EXPERIMENTAL
Intervention: HbA1c values between 8.1 and 8.6% (65-70 mmol/mol).
Number of subjects: 0
Study 29191845 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower HbA1c values.
Number of subjects: 0
Study 26869288 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise training (ET) program for 12 weeks
Number of subjects: 34
Study 26869288 — intervention group
Group type: COMPARATOR
Intervention: Regular medical treatment (Control)
Number of subjects: 34
Study 24869609 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine infusion preoperatively and throughout surgery
Number of subjects: 36
Study 24869609 — intervention group
Group type: COMPARATOR
Intervention: Normal saline infusion (placebo)
Number of subjects: 36
Study 23115768 — intervention group
Group type: EXPERIMENTAL
Intervention: Mucoperiosteal flap
Number of subjects: 40
Study 23115768 — intervention group
Group type: COMPARATOR
Intervention: Flapless buccal surgery
Number of subjects: 40
Study 20682671 — intervention group
Group type: COMPARATOR
Intervention: Immediate-release (IR) prednisone
Number of subjects: 28
Study 20682671 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified-release (MR) prednisone
Number of subjects: 28
Study 17704660 — intervention group
Group type: EXPERIMENTAL
Intervention: Assay-directed therapy
Number of subjects: 180
Study 17704660 — intervention group
Group type: COMPARATOR
Intervention: Physician's-choice chemotherapy
Number of subjects: 180
Study 15353050 — intervention group
Group type: EXPERIMENTAL
Intervention: CRP rapid test used by GPs (77% of GPs, n = 281)
Number of subjects: 1444
Study 15353050 — intervention group
Group type: COMPARATOR
Intervention: No CRP rapid test used by GPs (23% of GPs)
Number of subjects: 1444
Study 11396371 — intervention group
Group type: EXPERIMENTAL
Intervention: Unkei-to
Number of subjects: 100
Study 11396371 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 100
Study 9926634 — intervention group
Group type: EXPERIMENTAL
Intervention: Twin Block appliance
Number of subjects: 47
Study 9926634 — intervention group
Group type: EXPERIMENTAL
Intervention: Bionator appliance
Number of subjects: 47
Study 9926634 — intervention group
Group type: EXPERIMENTAL
Intervention: Bass appliance
Number of subjects: 47
Study 9926634 — intervention group
Group type: EXPERIMENTAL
Intervention: All appliance groups
Number of subjects: 47
Study 9926634 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 47
Study 7851219 — intervention group
Group type: EXPERIMENTAL
Intervention: tolrestat (200 mg once daily)
Number of subjects: 31
Study 7851219 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 31
Study 3183072 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam 10 mg
Number of subjects: 6
Study 3183072 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 31837066 — intervention group
Group type: EXPERIMENTAL
Intervention: Formal Sector Social Health Insurance Programme (FSSHIP)
Number of subjects: 333
Study 31837066 — intervention group
Group type: COMPARATOR
Intervention: Out-of-pocket (OOP) payments
Number of subjects: 333
Study 29035220 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-applied force vector field intervention
Number of subjects: 11
Study 29035220 — intervention group
Group type: COMPARATOR
Intervention: Control group (trained without forces)
Number of subjects: 11
Study 28727643 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based intervention delivered by teachers
Number of subjects: 190
Study 28727643 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 190
Study 26027780 — intervention group
Group type: EXPERIMENTAL
Intervention: Illiterate patients
Number of subjects: 422
Study 26027780 — intervention group
Group type: COMPARATOR
Intervention: Literates
Number of subjects: 422
Study 26027780 — intervention group
Group type: COMPARATOR
Intervention: Female gender
Number of subjects: 422
Study 26027780 — intervention group
Group type: COMPARATOR
Intervention: History of foot ulcer
Number of subjects: 422
Study 23883161 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen
Number of subjects: 135
Study 23883161 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Number of subjects: 135
Study 21951770 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitation intervention targeting healthcare staff and community representatives over 3 years.
Number of subjects: 90
Study 21951770 — intervention group
Group type: COMPARATOR
Intervention: Control arm (not specified in detail).
Number of subjects: 90
Study 18303059 — intervention group
Group type: EXPERIMENTAL
Intervention: Asymmetric-asymptomatic group (n=6)
Number of subjects: 34
Study 18303059 — intervention group
Group type: EXPERIMENTAL
Intervention: Asymmetric-symptomatic group (n=5)
Number of subjects: 34
Study 18303059 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=7)
Number of subjects: 34
Study 17144957 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoroscopy-guided location of heel spur for ESWT
Number of subjects: 41
Study 17144957 — intervention group
Group type: COMPARATOR
Intervention: Patient location of maximal point of tenderness for ESWT
Number of subjects: 41
Study 14628987 — intervention group
Group type: EXPERIMENTAL
Intervention: Group psychoeducation
Number of subjects: 25
Study 14628987 — intervention group
Group type: COMPARATOR
Intervention: Control group (no psychoeducation)
Number of subjects: 25
Study 10863680 — intervention group
Group type: EXPERIMENTAL
Intervention: Hardiness, avoidance coping, and approach coping
Number of subjects: 381
Study 9094877 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactitol
Number of subjects: 8
Study 9094877 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylitol
Number of subjects: 8
Study 9094877 — intervention group
Group type: COMPARATOR
Intervention: Glucose
Number of subjects: 8
Study 8456144 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined training (n = 12): vigorous program of lower‐extremity strengthening, walking briskly for 20 minutes, and postural control exercises (including tai chi movements)
Number of subjects: 21
Study 8456144 — intervention group
Group type: COMPARATOR
Intervention: Flexibility training (n = 9): performed postural control exercises weekly
Number of subjects: 21
Study 3541091 — intervention group
Group type: EXPERIMENTAL
Intervention: sobrerol 300 mg b.i.d. for 3 months
Number of subjects: 706
Study 3541091 — intervention group
Group type: COMPARATOR
Intervention: placebo b.i.d. for 3 months
Number of subjects: 706
Study 31167863 — intervention group
Group type: EXPERIMENTAL
Intervention: ICAN QUIT in Pregnancy intervention (three 1-hour webinar sessions, educational resource package, and free oral NRT)
Number of subjects: 50
Study 31167863 — intervention group
Group type: EXPERIMENTAL
Intervention: ICAN QUIT in Pregnancy intervention
Number of subjects: 50
Study 29893488 — intervention group
Group type: EXPERIMENTAL
Intervention: Semaglutide
Number of subjects: 38
Study 29893488 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 27310332 — intervention group
Group type: EXPERIMENTAL
Intervention: CTP-499 (600 mg orally once daily for 2 weeks, then twice daily for 2 additional weeks)
Number of subjects: 33
Study 27310332 — intervention group
Group type: COMPARATOR
Intervention: Placebo (matching tablets)
Number of subjects: 33
Study 25209344 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobi‐C disc prosthesis replacement
Number of subjects: 111
Study 25209344 — intervention group
Group type: COMPARATOR
Intervention: ACDF
Number of subjects: 111
Study 23107225 — intervention group
Group type: EXPERIMENTAL
Intervention: Incredible Years parent training
Number of subjects: 0
Study 23107225 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 20923244 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin/metformin 50 mg/500 mg FDC tablet
Number of subjects: 48
Study 20923244 — intervention group
Group type: COMPARATOR
Intervention: Sitagliptin 50 mg and metformin 500 mg co-administration
Number of subjects: 48
Study 20923244 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin/metformin 50 mg/1000 mg FDC tablet
Number of subjects: 48
Study 20923244 — intervention group
Group type: COMPARATOR
Intervention: Sitagliptin 50 mg and metformin 1000 mg co-administration
Number of subjects: 48
Study 18611989 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative number of contrast enhancing lesions (CEL) evolving into a persistent black hole (PBH) after 3 months
Number of subjects: 169
Study 18611989 — intervention group
Group type: EXPERIMENTAL
Intervention: Ring enhancing lesions
Number of subjects: 169
Study 18611989 — intervention group
Group type: EXPERIMENTAL
Intervention: Lesions larger than 10 mm
Number of subjects: 169
Study 18611989 — intervention group
Group type: EXPERIMENTAL
Intervention: Periventricular CELs
Number of subjects: 169
Study 18611989 — intervention group
Group type: EXPERIMENTAL
Intervention: Statistical simulation for sample sizes
Number of subjects: 169
Study 15957835 — intervention group
Group type: EXPERIMENTAL
Intervention: Shenfu injection (SFI) - 40 ml intravenous injection, once a day for 7 days
Number of subjects: 93
Study 15957835 — intervention group
Group type: COMPARATOR
Intervention: Control group - PCI only
Number of subjects: 93
Study 11818154 — intervention group
Group type: EXPERIMENTAL
Intervention: Leishvacin plus rhGM‐CSF
Number of subjects: 56
Study 11818154 — intervention group
Group type: COMPARATOR
Intervention: Leishvacin plus placebo
Number of subjects: 56
Study 11818154 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall group
Number of subjects: 56
Study 10190773 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated front‐crawl arm‐pulling
Number of subjects: 16
Study 10190773 — intervention group
Group type: COMPARATOR
Intervention: Simulated leg‐kicking
Number of subjects: 16
Study 7759696 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil capsules (6 g of n‐3 fatty acids)
Number of subjects: 59
Study 7759696 — intervention group
Group type: COMPARATOR
Intervention: Olive oil capsules (control)
Number of subjects: 59
Study 7759696 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil capsules
Number of subjects: 59
Study 2322153 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasocon‐A (0.05% naphazoline hydrochloride and 0.5% antazoline phosphate)
Number of subjects: 100
Study 2322153 — intervention group
Group type: COMPARATOR
Intervention: 0.05% naphazoline
Number of subjects: 100
Study 2322153 — intervention group
Group type: COMPARATOR
Intervention: 0.5% antazoline
Number of subjects: 100
Study 2322153 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 365665 — intervention group
Group type: EXPERIMENTAL
Intervention: Antacid (aluminum‐magnesium hydroxide tablets, 800 mg seven times per day)
Number of subjects: 101
Study 365665 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulpiride (hypothalamic neurolaptic)
Number of subjects: 101
Study 365665 — intervention group
Group type: EXPERIMENTAL
Intervention: Antacid-sulpiride combination
Number of subjects: 101
Study 365665 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study 30610279 — intervention group
Group type: EXPERIMENTAL
Intervention: R-CHOP plus 8 doses of rituximab
Number of subjects: 616
Study 27810902 — intervention group
Group type: EXPERIMENTAL
Intervention: TT4‐S (standard arm)
Number of subjects: 289
Study 27810902 — intervention group
Group type: COMPARATOR
Intervention: TT4‐L (light arm)
Number of subjects: 289
Study 25579609 — intervention group
Group type: EXPERIMENTAL
Intervention: CBM-I with 0 letters missing
Number of subjects: 350
Study 25579609 — intervention group
Group type: EXPERIMENTAL
Intervention: CBM-I with 1 letter missing
Number of subjects: 350
Study 25579609 — intervention group
Group type: EXPERIMENTAL
Intervention: CBM-I with 2 letters missing
Number of subjects: 350
Study 25579609 — intervention group
Group type: EXPERIMENTAL
Intervention: CBM-I with 3 letters missing
Number of subjects: 350
Study 25579609 — intervention group
Group type: COMPARATOR
Intervention: Control condition (half scenarios ended positively, half negatively)
Number of subjects: 350
Study 23703722 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplements (up to 1000 mg/d)
Number of subjects: 9033